Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Taxes (2016 - 2020)

Myriad Genetics has reported Current Taxes over the past 7 years, most recently at $6.1 million for Q2 2020.

  • Quarterly Current Taxes rose 103.33% to $6.1 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $6.1 million through Jun 2020, up 103.33% year-over-year, with the annual reading at $6.1 million for FY2020, 103.33% up from the prior year.
  • Current Taxes was $6.1 million for Q2 2020 at Myriad Genetics, up from $3.5 million in the prior quarter.
  • Over five years, Current Taxes peaked at $9.8 million in Q3 2018 and troughed at $2.3 million in Q1 2016.
  • The 5-year median for Current Taxes is $3.6 million (2019), against an average of $4.6 million.
  • Year-over-year, Current Taxes surged 168.75% in 2017 and then plummeted 39.44% in 2018.
  • A 5-year view of Current Taxes shows it stood at $3.0 million in 2016, then grew by 6.67% to $3.2 million in 2017, then soared by 53.12% to $4.9 million in 2018, then decreased by 18.37% to $4.0 million in 2019, then surged by 52.5% to $6.1 million in 2020.
  • Per Business Quant, the three most recent readings for MYGN's Current Taxes are $6.1 million (Q2 2020), $3.5 million (Q1 2020), and $4.0 million (Q4 2019).